Jones T. Nauseef

Hematology | Oncology
520 E 70th St
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications

Deep learning-based histologic classifiers enable molecular subtyping of metastatic prostate cancer.

Deep learning-based histologic classifiers enable molecular subtyping of metastatic prostate cancer.

Journal: JCI insight
Published: August 06, 2026

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.

Journal: Science advances
Published: June 26, 2026

A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancer.

A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 17, 2026

Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.

Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 26, 2026

Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer.

Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer.

Journal: JCO precision oncology
Published: December 05, 2025

Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancer.

Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancer.

Journal: medRxiv : the preprint server for health sciences
Published: July 09, 2025

Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617.

Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617.

Journal: The oncologist
Published: June 27, 2025

A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials.

A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials.

Journal: Future oncology (London, England)
Published: February 24, 2025

A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution.

A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution.

Journal: European urology oncology
Published: February 16, 2025

A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution.

A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution.

Journal: European urology oncology
Published: February 16, 2025

Mesonephric Adenocarcinoma in a Young Male Patient.

Mesonephric Adenocarcinoma in a Young Male Patient.

Journal: Anticancer research
Published: November 05, 2024

Baseline Imaging Derived Factors of Response Following [225Ac]Ac-J591 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Lesion Level Analysis.

Baseline Imaging Derived Factors of Response Following [225Ac]Ac-J591 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Lesion Level Analysis.

Journal: The Prostate
Published: August 26, 2024
Showing 1-12 of 31

Last Updated: 09/26/2026